Yarranton; Geoffrey T.
Patent Applications and Registrations
Patent applications and USPTO patent grants for Yarranton; Geoffrey T..The latest application filed is for "epha3 antibodies for the treatment of pulmonary fibrosis".
Company Profile
1.36.46
- Yarranton; Geoffrey T. - Burlingame CA
- YARRANTON; Geoffrey T - Burlingame CA
- Yarranton; Geoffrey T. - Brisbane CA
- Yarranton; Geoffrey T. - South San Francisco CA
- Yarranton; Geoffrey T. - South Francisco CA
- Yarranton; Geoffrey T. - Winnersh GB
Patent Activity
| Patent | Date |
|---|---|
| Immunoglobulin variable region cassette exchange Grant 10,919,983 - Bebbington , et al. February 16, 2 | 2021-02-16 |
| Epha3 Antibodies For The Treatment Of Pulmonary Fibrosis App 20190270821 - YARRANTON; Geoffrey T | 2019-09-05 |
| Detection of EphA3 as a Marker of the Presence of a Solid Tumor App 20170335001 - Lackmann; Martin ; et al. | 2017-11-23 |
| Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3 App 20170226227 - Bebbington; Christopher R. ; et al. | 2017-08-10 |
| Immunoglobulin Variable Region Cassette Exchange App 20160102152 - Bebbington; Christopher Robert ; et al. | 2016-04-14 |
| Antibodies to EphA3 Grant 9,290,571 - Luehrsen , et al. March 22, 2 | 2016-03-22 |
| Antibodies To Granulocyte-macrophage Colony-stimulating Factor App 20150344565 - Bebbington; Christopher R. ; et al. | 2015-12-03 |
| Methods of Treating Hematological Proliferative Disorders by Targeting EphA3 Expressed on Aberrant Vasculature in Bone Marrow App 20150329647 - Yarranton; Geoffrey T. ; et al. | 2015-11-19 |
| Secretion of antibodies without signal peptides from bacteria Grant 9,127,046 - Yarranton , et al. September 8, 2 | 2015-09-08 |
| Methods Of Treating Chronic Inflammatory Diseases Using A Gm-csf Antagonist App 20150246121 - Bebbington; Christopher R. ; et al. | 2015-09-03 |
| Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow Grant 9,109,032 - Yarranton , et al. August 18, 2 | 2015-08-18 |
| Anti-EMR1 antibodies Grant 9,045,539 - Luehrsen , et al. June 2, 2 | 2015-06-02 |
| Antibodies To The Pcrv Antigen Of Pseudomonas Aeruginosa App 20150030614 - Bebbington; Christopher R. ; et al. | 2015-01-29 |
| Treatment Of Leukemias And Chronic Myeloproliferative Diseases With Antibodies To Epha3 App 20140370010 - Bebbington; Christopher R. ; et al. | 2014-12-18 |
| Antibodies to the PcrV antigen of Pseudomonas aeruginosa Grant 8,877,191 - Bebbington , et al. November 4, 2 | 2014-11-04 |
| Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3 Grant 8,834,870 - Bebbington , et al. September 16, 2 | 2014-09-16 |
| Methods for the therapy of inflammatory bowel disease using a type-1 interferon antagonist Grant 8,828,393 - Pickford , et al. September 9, 2 | 2014-09-09 |
| Antibodies to EphA3 App 20140120114 - Luehrsen; Kenneth ; et al. | 2014-05-01 |
| Antibodies to EphA3 Grant 8,664,365 - Luehrsen , et al. March 4, 2 | 2014-03-04 |
| Method of treating a staphylococcus infection in a patient having a low-level pathogenic Pseudomonas aeruginosa infection Grant 8,642,039 - Yarranton February 4, 2 | 2014-02-04 |
| EphA3 antibodies for the treatment of solid tumors Grant 8,637,016 - Lackmann , et al. January 28, 2 | 2014-01-28 |
| Methods Of Treating Dementia Using A Gm-csf Antagonist App 20130156759 - Bebbington; Christopher R. ; et al. | 2013-06-20 |
| Generation Of Antibodies To An Epitope Of Interest That Contains A Phosphomimetic Amino Acid App 20130109586 - Luehrsen; Kenneth ; et al. | 2013-05-02 |
| Methods of treating dementia using a GM-CSF antagonist Grant 8,398,972 - Bebbington , et al. March 19, 2 | 2013-03-19 |
| Anti-emr1 Antibodies App 20130064826 - Luehrsen; Kenneth ; et al. | 2013-03-14 |
| Methods Of Treating Hematological Proliferative Disorders By Targeting Epha3 Expressed On Aberrant Vasculature In Bone Marrow App 20130039907 - Yarranton; Geoffrey T. ; et al. | 2013-02-14 |
| Secretion of antibodies without signal peptides from bacteria App 20120309055 - Yarranton; Geoffrey T. ; et al. | 2012-12-06 |
| Antibodies To Granulocyte-macrophage Colony-stimulating Factor App 20120213776 - Bebbington; Christopher R. ; et al. | 2012-08-23 |
| Secretion of antibodies without signal peptides from bacteria Grant 8,211,648 - Yarranton , et al. July 3, 2 | 2012-07-03 |
| Antibodies to granulocyte-macrophage colony-stimulating factor Grant 8,168,183 - Bebbington , et al. May 1, 2 | 2012-05-01 |
| Antibodies to the PcrV Antigen of Pseudomonas aeruginosa App 20120020986 - Bebbington; Christopher R. ; et al. | 2012-01-26 |
| Methods Of Treating Bone-loss Disorders Using A Gm-csf Antagonist App 20120009191 - Bebbington; Christopher R. ; et al. | 2012-01-12 |
| Detection Of Epha3 As A Marker Of The Presence Of A Solid Tumor App 20110318304 - Lackmann; Martin ; et al. | 2011-12-29 |
| Methods of treating heart failure using an anti-GM-CSF antibody Grant 8,075,885 - Bebbington , et al. December 13, 2 | 2011-12-13 |
| Antibodies to the PcrV antigen of Pseudomonas aeruginosa Grant 8,044,181 - Bebbington , et al. October 25, 2 | 2011-10-25 |
| Enzyme-cleavable prodrug compounds Grant 8,034,787 - Dubois , et al. October 11, 2 | 2011-10-11 |
| Generation Of Antibodies To An Epitope Of Interest App 20110245100 - Yarranton; Geoffrey T. ; et al. | 2011-10-06 |
| Antibody specificity transfer using minimal essential binding determinants Grant 7,981,843 - Flynn , et al. July 19, 2 | 2011-07-19 |
| Method Of Treating A Staphylococcus Infection In A Patient Having A Low-level Pathogenic Pseudomonas Aeruginosa Infection App 20110165172 - Yarranton; Geoffrey T. | 2011-07-07 |
| Methods For The Therapy Of Inflammatory Bowel Disease Using A Type-1 Interferon Antagonist App 20110165158 - Pickford; Lesley B. ; et al. | 2011-07-07 |
| Antibodies to EphA3 App 20110123549 - Luehrsen; Kenneth ; et al. | 2011-05-26 |
| Methods for the therapy of Inflammatory Bowel Disease using a type-1 interferon antagonist Grant 7,939,076 - Pickford , et al. May 10, 2 | 2011-05-10 |
| Combination Antibiotic And Antibody Therapy For The Treatment Of Pseudomonas Aeruginosa Infection App 20100272736 - Baer; Mark ; et al. | 2010-10-28 |
| Tripeptide prodrug compounds Grant 7,816,317 - Bebbington , et al. October 19, 2 | 2010-10-19 |
| Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3 App 20100226930 - Bebbington; Christopher R. ; et al. | 2010-09-09 |
| Methods Of Treating Dementia Using A Gm-csf Antagonist App 20100215650 - Bebbington; Christopher R. ; et al. | 2010-08-26 |
| Prodrug compounds with isoleucine Grant 7,696,313 - Pickford , et al. April 13, 2 | 2010-04-13 |
| Antibodies To Granulocyte-macrophage Colony-stimulating Factor App 20090274706 - Bebbington; Christopher R. ; et al. | 2009-11-05 |
| Neutralization of GM-CSF for the Treatment of Heart Failure App 20090263387 - Bebbington; Christopher R. ; et al. | 2009-10-22 |
| Antibodies to the PcrV Antigen of Pseudomonas aeruginosa App 20090191186 - Bebbington; Christopher R. ; et al. | 2009-07-30 |
| Methods of Treating Bone-Loss Disorders Using a GM-CSF Antagonist App 20090181020 - BEBBINGTON; Christopher R. ; et al. | 2009-07-16 |
| Enzyme-cleavable prodrug compounds App 20090110753 - Dubois; Vincent ; et al. | 2009-04-30 |
| EphA3 Antibodies for the Treatment of Solid Tumors App 20080286272 - Lackmann; Martin ; et al. | 2008-11-20 |
| Prodrug compounds with isoleucine App 20080255248 - Pickford; Lesley B. ; et al. | 2008-10-16 |
| Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist App 20080206241 - Bebbington; Christopher R. ; et al. | 2008-08-28 |
| Methods Of Treating Idiopathic Thrombocytopenia Purpura Using A Gm-csf Antagonist App 20080171038 - Bebbington; Christopher R. ; et al. | 2008-07-17 |
| Prodrug compounds with isoleucine Grant 7,329,507 - Pickford , et al. February 12, 2 | 2008-02-12 |
| Tripeptide prodrug compounds App 20070275903 - Bebbington; Christopher R. ; et al. | 2007-11-29 |
| Tripeptide prodrug compounds Grant 7,214,663 - Bebbington , et al. May 8, 2 | 2007-05-08 |
| Secretion of antibodies without signal peptides from bacteria App 20070020685 - Yarranton; Geoffrey T. ; et al. | 2007-01-25 |
| Prodrug compounds with isoleucine App 20070020694 - Pickford; Lesley B. ; et al. | 2007-01-25 |
| Cytotoxic agents Grant 7,129,261 - Ng , et al. October 31, 2 | 2006-10-31 |
| Prodrug compounds with an isoleucine Grant 7,115,573 - Pickford , et al. October 3, 2 | 2006-10-03 |
| Antibody specificity transfer using minimal essential binding determinants App 20050255552 - Flynn, Peter ; et al. | 2005-11-17 |
| Compositions and methods for the therapy of Inflammatory Bowel Disease App 20050152901 - Pickford, Lesley B. ; et al. | 2005-07-14 |
| Prodrug compounds with an oligopeptide having an isoluecine residue App 20040039160 - Pickford, Lesley B. ; et al. | 2004-02-26 |
| Tripeptide prodrug compounds App 20030181359 - Bebbington, Christopher R. ; et al. | 2003-09-25 |
| Cytotoxic agents App 20030050331 - Ng, Howard P. ; et al. | 2003-03-13 |
| Enzyme-cleavable prodrug compounds App 20020142955 - Dubois, Vincent ; et al. | 2002-10-03 |
| DNA vectors and their use in recombinant DNA technology Grant 5,015,573 - Yarranton , et al. May 14, 1 | 1991-05-14 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 